

chain nodes :

12 13 14 16

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

3-7 6-13 9-12 11-16 13-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11

exact/norm bonds :

3-7 7-8 7-11 8-9 9-10 10-11 11-16 13-14

exact bonds :

6-13 9-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 :

G1:H,NH2,NH3,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS
13:CLASS 14:CLASS 16:Atom

10/633,083

=> d his

(FILE 'HOME' ENTERED AT 10:31:03 ON 11 JUL 2006)

FILE 'REGISTRY' ENTERED AT 10:31:22 ON 11 JUL 2006

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 130 S L1 SSS FUL

L4 130 S L3 AND CAPLUS/LC


FILE 'CAPLUS' ENTERED AT 10:32:20 ON 11 JUL 2006

L5 5 S L4

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 H, NH₂, NH₃, Ak

Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

10/633,083

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:453194 CAPLUS

DOCUMENT NUMBER: 141:7124

TITLE: Preparation of 1,2,4-triazoles as Cyclooxygenase-2 (COX-2) inhibitors for treating fever, pain and inflammation

INVENTOR(S): Cho, Il-hwan; Ko, Dong-hyun; Chae, Myeong-yun; Kim, Tae-rho; Kang, Kyoung-rae; Kim, Jong-hoon; Jung, Sung-hak; Park, Sang-wook; Chun, Hyung-ok; Ryu, Hyung-chul; Noh, Ji-young; Park, Hyun-jung; Park, Jie-eun; Chung, Young-mee

PATENT ASSIGNEE(S): CJ Corporation, S. Korea

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046121	A1	20040603	WO 2003-KR1514	20030729
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
KR 2004044614	A	20040531	KR 2002-72688	20021121
AU 2003256091	A1	20040615	AU 2003-256091	20030729
EP 1567508	A1	20050831	EP 2003-811548	20030729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1717397	A	20060104	CN 2003-825694	20030729
JP 2006514631	T2	20060511	JP 2004-553243	20030729
US 6849652	B1	20050201	US 2003-631594	20030731
PRIORITY APPLN. INFO.:			KR 2002-72688	A 20021121
			WO 2003-KR1514	W 20030729
OTHER SOURCE(S):	MARPAT 141:7124			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein Ar = naphthyl, 3,4-methylenedioxyphenyl, (un)substituted Ph; and their non-toxic salts] were prepared as Cyclooxygenase-2 (COX-2) inhibitors for treating fever, pain and inflammation. For example, II was prepared by cyclocondensation of acetamidrazone III with benzoyl chloride in Py, and oxidation with MMPP in CH₂Cl₂. * Inhibition ratios of COX-2 to COX-1 for compds. I were significantly higher than that in Valdecixib. Thus, I are useful for treating fever, pain, inflammation, neoplasm, and dementia.

IT 696602-82-1P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-phenyl-3-trifluoromethyl-1H-1,2,4-triazole 696602-89-8P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1,2,4-triazole 696602-96-7P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(4-fluorophenyl)-3-


trifluoromethyl-1H-1,2,4-triazole 696603-03-9P,
 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(4-bromophenyl)-3-trifluoromethyl-
 1H-1,2,4-triazole 696603-09-5P, 1-[3-Fluoro-4-
 (methanesulfonyl)phenyl]-5-(4-chlorophenyl)-3-trifluoromethyl-1H-1,2,4-
 triazole 696603-17-5P, 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-
 (4-methylphenyl)-3-trifluoromethyl-1H-1,2,4-triazole 696603-24-4P
 , 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(4-ethoxyphenyl)-3-
 trifluoromethyl-1H-1,2,4-triazole 696603-32-4P,
 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(3-chlorophenyl)-3-
 trifluoromethyl-1H-1,2,4-triazole 696603-41-5P,
 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(3-fluorophenyl)-3-
 trifluoromethyl-1H-1,2,4-triazole 696603-48-2P,
 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-3-
 trifluoromethyl-1H-1,2,4-triazole 696603-54-0P,
 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(3-methylphenyl)-3-
 trifluoromethyl-1H-1,2,4-triazole 696603-61-9P,
 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(naphthalen-2-yl)-3-
 trifluoromethyl-1H-1,2,4-triazole 696603-69-7P,
 5-([1,3]Benzodioxol-5-yl)-1-[3-fluoro-4-(methanesulfonyl)phenyl]-3-
 trifluoromethyl-1H-1,2,4-triazole 696603-74-4P,
 1-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-(3,4-difluorophenyl)-3-
 trifluoromethyl-1H-1,2,4-triazole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(COX-2 inhibitor; preparation of triazoles as selective COX-2 inhibitors for
 treating fever, pain and inflammation)


RN 696602-82-1 CAPLUS

CN 1H-1,2,4-Triazole, 1-[3-fluoro-4-(methylsulfonyl)phenyl]-5-phenyl-3-
 (trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 696602-89-8 CAPLUS


CN 1H-1,2,4-Triazole, 1-[3-fluoro-4-(methylsulfonyl)phenyl]-5-(4-
 methoxyphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



10/633,083


RN 696602-96-7 CAPLUS

CN 1H-1,2,4-Triazole, 1-[3-fluoro-4-(methylsulfonyl)phenyl]-5-(4-fluorophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 696603-03-9 CAPLUS

CN 1H-1,2,4-Triazole, 5-(4-bromophenyl)-1-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 696603-09-5 CAPLUS


CN 1H-1,2,4-Triazole, 5-(4-chlorophenyl)-1-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



10/633,083


RN 696603-17-5 CAPLUS

CN 1H-1,2,4-Triazole, 1-[3-fluoro-4-(methylsulfonyl)phenyl]-5-(4-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 696603-24-4 CAPLUS

CN 1H-1,2,4-Triazole, 5-(4-ethoxyphenyl)-1-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 696603-32-4 CAPLUS


CN 1H-1,2,4-Triazole, 5-(3-chlorophenyl)-1-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 696603-41-5 CAPLUS


10/633,083

CN 1H-1,2,4-Triazole, 1-[3-fluoro-4-(methylsulfonyl)phenyl]-5-(3-fluorophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 696603-48-2 CAPLUS

CN 1H-1,2,4-Triazole, 5-(3-fluoro-4-methoxyphenyl)-1-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 696603-54-0 CAPLUS


CN 1H-1,2,4-Triazole, 1-[3-fluoro-4-(methylsulfonyl)phenyl]-5-(3-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 696603-61-9 CAPLUS


CN 1H-1,2,4-Triazole, 1-[3-fluoro-4-(methylsulfonyl)phenyl]-5-(2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 696603-69-7 CAPLUS

CN 1H-1,2,4-Triazole, 5-(1,3-benzodioxol-5-yl)-1-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 696603-74-4 CAPLUS


CN 1H-1,2,4-Triazole, 5-(3,4-difluorophenyl)-1-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



10/633,083

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:451632 CAPLUS
DOCUMENT NUMBER: 141:23536
TITLE: Preparation of 1,2,4-triazole derivatives as selective COX-2 inhibitors
INVENTOR(S): Cho, Il Hwan; Ko, Dong Hyun; Chae, Myeong Yun; Kim, Taerho; Kang, Kyoung Rae; Kim, Jong Hoon; Jung, Sung Hak; Park, Sang Wook; Chun, Hyung Ok; Ryu, Hyung Chul; Noh, Ji Young; Park, Hyun Jung; Park, Jie Eun; Chung, Young Mee
PATENT ASSIGNEE(S): S. Korea
SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004106612	A1	20040603	US 2003-633083	20030801
WO 2004048367	A1	20040610	WO 2003-KR1530	20030730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003251172	A1	20040618	AU 2003-251172	20030730
EP 1565456	A1	20050824	EP 2003-811956	20030730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1717404	A	20060104	CN 2003-825718	20030730
JP 2006511507	T2	20060406	JP 2004-555085	20030730
PRIORITY APPLN. INFO.:			KR 2002-74118	A 20021126
			WO 2003-KR1530	W 20030730
OTHER SOURCE(S):		MARPAT 141:23536		
GI				



AB The title compds. [I; R1 = (un)substituted naphthyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzotriazolyl, benzooxazolyl, quinolinyl, isoquinolinyl; R2 = Me, NH2; A, B, C, D = C, N] which showed selective inhibition of COX-2 to COX-1, were prepared E.g., a 3-step synthesis of I [R1 = 2-naphthyl; R2 = Me; A, B, C, D = CH], starting from 4-methylsulfanylphenylhydrazine.HCl and

10/633,083

trifluoroacetimidine, which showed 12.3% COX-2 inhibition at 10 nM vs. 26.2% COX-1 inhibition at 1 μ M, was given.


IT 698350-38-8P 698350-39-9P 698350-40-2P
698350-41-3P 698350-42-4P 698350-43-5P
698350-44-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,2,4-triazole derivs. as selective COX-2 inhibitors)


RN 698350-38-8 CAPLUS

CN 1H-1,2,4-Triazole, 1-[4-(methylsulfonyl)phenyl]-5-(2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 698350-39-9 CAPLUS


CN 1H-1,2,4-Triazole, 5-(2-benzofuranyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 698350-40-2 CAPLUS


CN 1H-Indole, 2-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 698350-41-3 CAPLUS

CN 1H-Indole, 1-methyl-2-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)



RN 698350-42-4 CAPLUS


CN 1H-Indole, 1-methyl-3-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)



RN 698350-43-5 CAPLUS


10/633,083

CN Quinoline, 2-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)



RN 698350-44-6 CAPLUS

CN Benzenesulfonamide, 4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



10/633,083

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:143123 CAPLUS

DOCUMENT NUMBER: 140:181455

TITLE: Preparation of 1-(hetero)aryl-3-trifluoromethyl-1H-1,2,4-triazoles as cyclooxygenase-2 selective inhibitors

INVENTOR(S): Cho, Il-hwan; Park, Hyun-jung; Noh, Ji-young; Ryu, Hyung-chul; Park, Sang-wook; Jung, Sung-hak; Lee, Sung-hak; Kim, Jong-hoon; Lim, Jee-woong; Lyu, Chun-seon; Kim, Dal-hyun; Kim, Young-hoon; Yeon, Kyu-jeong; Chae, Myeong-yun; Min, In-ki; Jin, Hae-tak; Kang, Kyoung-rae

PATENT ASSIGNEE(S): Cj Corporation, S. Korea

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014878	A1	20040219	WO 2003-KR1183	20030617
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2494321	AA	20040219	CA 2003-2494321	20030617
AU 2003243022	A1	20040225	AU 2003-243022	20030617
EP 1539718	A1	20050615	EP 2003-784655	20030617
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003013215	A	20050726	BR 2003-13215	20030617
CN 1688554	A	20051026	CN 2003-823852	20030617
JP 2006505521	T2	20060216	JP 2004-527410	20030617
US 2005075507	A1	20050407	US 2003-608709	20030627
US 7019144	B2	20060328		

PRIORITY APPLN. INFO.:


KR 2002-46551 A 20020807
WO 2003-KR1183 W 20030617

OTHER SOURCE(S): MARPAT 140:181455

GI



- AB Title amidrazone derivs. I [wherein R1 = cycloalkyl, cycloalkenyl, (un)substituted Ph, (alkoxy)styrenyl, or pyridyl; R2 = Me or NH₂; A, B, C, and D = independently C or N; or a nontoxic salt thereof] were prepared as cyclooxygenase-2 (COX-2) selective inhibitors. For example, oxidation of 5-(4-ethoxyphenyl)-1-(4-methylsulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole using 80% MMPP in CH₂Cl₂ gave the methanesulfonylphenyl derivative II (82%). The latter selectively inhibited COX-2 (38.65%) to COX-1 (11.8%). In addition, II suppressed carrageenan-induced paw edema in rats by 32.3%, compared to 23.9% suppression by the celecoxib reference. Thus, I and their pharmaceutical compns. are useful in the treatment of fever, pain, inflammation, cancer, and dementia (no data).
- IT 660400-58-8P, 1-[4-(Methanesulfonyl)phenyl]-5-(p-tolyl)-3-trifluoromethyl-1H-[1,2,4]triazole
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (COX inhibitor; preparation of triazoles as COX-2 inhibitors for treatment of fever, pain, inflammation, cancer, and dementia)
- RN 660400-58-8 CAPLUS
- CN 1H-1,2,4-Triazole, 5-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



- IT 481052-74-8P, 4-(5-Phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-76-0P, 4-[5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-81-7P, 4-[5-(4-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-87-3P, 4-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 660400-59-9P, 1-[4-(Methanesulfonyl)phenyl]-5-phenyl-3-trifluoromethyl-1H-[1,2,4]triazole 660400-60-2P, 5-(4-Chlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-61-3P, 5-(4-Bromophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-62-4P, 1-[4-(Methanesulfonyl)phenyl]-5-(4-methoxyphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole 660400-63-5P, 5-(3-Bromophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-64-6P, 5-(3-Chlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-65-7P, 5-(3-Trifluoromethylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-66-8P, 5-(2,4-Dimethoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-69-1P, 5-(4-Ethoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-70-4P, 5-(4-tert-Butylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-71-5P, 5-(4-Cyanophenyl)-1-[4-

(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-72-6P, 5-(4-Nitro-2-chlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-73-7P, 5-(3-Chloro-4-methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-74-8P, 5-(Benzodioxol-5-yl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-75-9P,
4-[2-[4-(Methanesulfonyl)phenyl]-5-trifluoromethyl-2H-[1,2,4]triazol-3-yl]pyridine 660400-76-0P, 4-[5-(p-Tolyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660400-77-1P,
4-[5-(4-Methoxyphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660400-78-2P 660400-85-1P,
5-(4-Fluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-86-2P, 5-(3,5-Dichloro-4-methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-87-3P, 5-(3,4-Dichlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-88-4P,
5-(3,4-Dimethoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-89-5P, 5-(3,4-Difluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660400-90-8P, 5-(3,4-Dimethylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-91-9P,
5-(3-Chloro-4-methylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-92-0P,
5-(4-Chloro-3-methylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-93-1P,
5-(4-Chloro-3-methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-94-2P,
5-(3-Fluoro-4-methylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-95-3P,
5-(4-Fluoro-3-methylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-96-4P,
5-(3-Fluoro-4-methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660400-97-5P,
1-[4-(Methanesulfonyl)phenyl]-3-trifluoromethyl-5-(4-trifluoromethylphenyl)-1H-[1,2,4]triazole 660400-98-6P,
1-[4-(Methanesulfonyl)phenyl]-5-(4-trifluoromethoxyphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole 660400-99-7P,
5-[4-(N-Methylamino)phenyl]-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-00-3P,
5-[4-(N,N-Dimethylamino)phenyl]-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-01-4P,
5-(4-Aminophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-02-5P, 5-(3-Methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660401-03-6P, 1-[4-(Methanesulfonyl)phenyl]-5-(m-tolyl)-3-trifluoromethyl-1H-[1,2,4]triazole 660401-04-7P,
1-[4-(Methanesulfonyl)phenyl]-5-(o-tolyl)-3-trifluoromethyl-1H-[1,2,4]triazole 660401-05-8P, 5-(2-Bromophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660401-06-9P, 5-(2-Methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-07-0P,
5-(2,4-Difluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-08-1P, 5-(2,5-Difluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660401-09-2P, 5-(2,4,5-Trifluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660401-10-5P, 5-(2,3-Dichlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-11-6P,
5-(2,4-Dichlorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-12-7P, 5-(3,5-Difluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660401-13-8P, 5-(3,5-Dimethoxyphenyl)-1-[4-

(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660401-14-9P, 5-(3,4,5-Trimethoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660401-15-0P, 5-(2-Fluoro-4-trifluoromethylphenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660401-16-1P, 5-(2,4-Dichloro-5-fluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660401-42-3P, 3-[2-[4-(Methanesulfonyl)phenyl]-5-trifluoromethyl-2H-[1,2,4]triazol-3-yl]pyridine 660401-43-4P,
5-Cyclohexyl-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole 660401-44-5P, 5-Cyclohexen-1-yl-1-[4-(methanesulfonyl)phenyl]-3-trifluoromethyl-1H-[1,2,4]triazole
660401-45-6P, 4-[5-(3,4-Difluorophenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-46-7P,
4-[5-(4-Chlorophenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-47-8P, 4-[5-(3,4-Dichlorophenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide
660401-48-9P, 4-[5-(3,4-Dimethoxyphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-49-0P,
4-[5-(3,4-Dimethylphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-50-3P, 4-[5-(3-Chloro-4-methylphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide
660401-51-4P, 4-[5-(4-Chloro-3-methylphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-52-5P,
4-[5-(3-Chloro-4-methoxyphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-53-6P, 4-[5-(4-Chloro-3-methoxyphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide
660401-54-7P, 4-[5-(3-Fluoro-4-methylphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-55-8P,
4-[5-(4-Fluoro-3-methylphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide 660401-56-9P, 4-[5-(3-Fluoro-4-methoxyphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide
660401-57-0P, 4-[5-(3,5-Dichloro-4-methoxyphenyl)-3-trifluoromethyl-1,2,4]triazol-1-yl]benzenesulfonamide
660401-58-1P, 4-[3-Trifluoromethyl-5-(4-trifluoromethylphenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-59-2P,
4-[3-Trifluoromethyl-5-(4-ethoxyphenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-60-5P, 4-[3-Trifluoromethyl-5-(4-trifluoromethoxyphenyl)-1,2,4]triazol-1-yl]benzenesulfonamide
660401-61-6P, 4-[3-Trifluoromethyl-5-(4-tert-butylphenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-62-7P,
4-[3-Trifluoromethyl-5-(4-cyanophenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-63-8P, 4-[3-Trifluoromethyl-5-(4-aminophenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-65-0P
, 4-[3-Trifluoromethyl-5-[4-(dimethylamino)phenyl]-1,2,4]triazol-1-yl]benzenesulfonamide 660401-66-1P, 4-[3-Trifluoromethyl-5-(m-tolyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-67-2P,
4-[3-Trifluoromethyl-5-(3-trifluoromethylphenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-68-3P, 4-[3-Trifluoromethyl-5-(3-methoxyphenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-69-4P
, 4-[3-Trifluoromethyl-5-(2-bromophenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-70-7P, 4-[3-Trifluoromethyl-5-(2-methoxyphenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-71-8P
, 4-[3-Trifluoromethyl-5-(2,4-difluorophenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-72-9P, 4-[3-Trifluoromethyl-5-(2,5-difluorophenyl)-1,2,4]triazol-1-yl]benzenesulfonamide
660401-73-0P, 4-[3-Trifluoromethyl-5-(2,4,5-trifluorophenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-74-1P,
4-[3-Trifluoromethyl-5-(2,3-dichlorophenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-75-2P, 4-[3-Trifluoromethyl-5-(2,4-dichlorophenyl)-1,2,4]triazol-1-yl]benzenesulfonamide
660401-76-3P, 4-[3-Trifluoromethyl-5-(3,5-dimethoxyphenyl)-1,2,4]triazol-1-yl]benzenesulfonamide 660401-77-4P,

10/633,083


4-[3-Trifluoromethyl-5-(2,4-dimethoxyphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-78-5P, 4-[3-Trifluoromethyl-5-(3,4,5-trifluorophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-79-6P, 4-[3-Trifluoromethyl-5-(2-fluoro-4-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-80-9P, 4-[3-Trifluoromethyl-5-(2-chloro-4-nitrophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-81-0P, 4-[3-Trifluoromethyl-5-(2,4-dichloro-5-fluorophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-82-1P, 4-[5-(Benzodioxol-5-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-83-2P, 4-[5-(Pyridin-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 660401-84-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(COX inhibitor; preparation of triazoles as COX-2 inhibitors for treatment of fever, pain, inflammation, cancer, and dementia)


RN 481052-74-8 CAPLUS

CN Benzenesulfonamide, 4-[5-phenyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-76-0 CAPLUS


CN Benzenesulfonamide, 4-[5-(3-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-81-7 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 481052-87-3 CAPLUS

CN Benzenesulfonamide, 4-[5-cyclohexyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660400-59-9 CAPLUS


CN 1H-1,2,4-Triazole, 1-[4-(methylsulfonyl)phenyl]-5-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-60-2 CAPLUS


CN 1H-1,2,4-Triazole, 5-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660400-61-3 CAPLUS

CN 1H-1,2,4-Triazole, 5-(4-bromophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-62-4 CAPLUS


CN 1H-1,2,4-Triazole, 5-(4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-63-5 CAPLUS


CN 1H-1,2,4-Triazole, 5-(3-bromophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660400-64-6 CAPLUS

CN 1H-1,2,4-Triazole, 5-(3-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-65-7 CAPLUS


CN 1H-1,2,4-Triazole, 1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 660400-66-8 CAPLUS


CN 1H-1,2,4-Triazole, 5-(2,4-dimethoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660400-69-1 CAPLUS

CN 1H-1,2,4-Triazole, 5-(4-ethoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-70-4 CAPLUS


CN 1H-1,2,4-Triazole, 5-[4-(1,1-dimethylethyl)phenyl]-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-71-5 CAPLUS


CN Benzonitrile, 4-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660400-72-6 CAPLUS

CN 1H-1,2,4-Triazole, 5-(2-chloro-4-nitrophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-73-7 CAPLUS


CN 1H-1,2,4-Triazole, 5-(3-chloro-4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-74-8 CAPLUS


CN 1H-1,2,4-Triazole, 5-(1,3-benzodioxol-5-yl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660400-75-9 CAPLUS

CN Pyridine, 4-[1-[4-(methanesulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)



RN 660400-76-0 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660400-77-1 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660400-78-2 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-bromophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660400-85-1 CAPLUS


CN 1H-1,2,4-Triazole, 5-(4-fluorophenyl)-1-[4-(methanesulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-86-2 CAPLUS


CN 1H-1,2,4-Triazole, 5-(3,5-dichloro-4-methoxyphenyl)-1-[4-(methanesulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660400-87-3 CAPLUS

CN 1H-1,2,4-Triazole, 5-(3,4-dichlorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-88-4 CAPLUS


CN 1H-1,2,4-Triazole, 5-(3,4-dimethoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-89-5 CAPLUS


CN 1H-1,2,4-Triazole, 5-(3,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660400-90-8 CAPLUS

CN 1H-1,2,4-Triazole, 5-(3,4-dimethylphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-91-9 CAPLUS


CN 1H-1,2,4-Triazole, 5-(3-chloro-4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-92-0 CAPLUS


CN 1H-1,2,4-Triazole, 5-(4-chloro-3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660400-93-1 CAPLUS

CN 1H-1,2,4-Triazole, 5-(4-chloro-3-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-94-2 CAPLUS


CN 1H-1,2,4-Triazole, 5-(3-fluoro-4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-95-3 CAPLUS


CN 1H-1,2,4-Triazole, 5-(4-fluoro-3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660400-96-4 CAPLUS

CN 1H-1,2,4-Triazole, 5-(3-fluoro-4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660400-97-5 CAPLUS


CN 1H-1,2,4-Triazole, 1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 660400-98-6 CAPLUS


CN 1H-1,2,4-Triazole, 1-[4-(methylsulfonyl)phenyl]-5-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660400-99-7 CAPLUS

CN Benzenamine, N-methyl-4-[1-[4-(methanesulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)



RN 660401-00-3 CAPLUS


CN Benzenamine, N,N-dimethyl-4-[1-[4-(methanesulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)



RN 660401-01-4 CAPLUS


CN Benzenamine, 4-[1-[4-(methanesulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-02-5 CAPLUS

CN 1H-1,2,4-Triazole, 5-(3-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660401-03-6 CAPLUS


CN 1H-1,2,4-Triazole, 5-(2-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660401-04-7 CAPLUS


CN 1H-1,2,4-Triazole, 5-(2-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-05-8 CAPLUS

CN 1H-1,2,4-Triazole, 5-(2-bromophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660401-06-9 CAPLUS


CN 1H-1,2,4-Triazole, 5-(2-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660401-07-0 CAPLUS


CN 1H-1,2,4-Triazole, 5-(2,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-08-1 CAPLUS

CN 1H-1,2,4-Triazole, 5-(2,5-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660401-09-2 CAPLUS


CN 1H-1,2,4-Triazole, 1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-5-(2,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 660401-10-5 CAPLUS


CN 1H-1,2,4-Triazole, 5-(2,3-dichlorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-11-6 CAPLUS

CN 1H-1,2,4-Triazole, 5-(2,4-dichlorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660401-12-7 CAPLUS


CN 1H-1,2,4-Triazole, 5-(3,5-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660401-13-8 CAPLUS


CN 1H-1,2,4-Triazole, 5-(3,5-dimethoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-14-9 CAPLUS

CN 1H-1,2,4-Triazole, 1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-5-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 660401-15-0 CAPLUS


CN 1H-1,2,4-Triazole, 5-[2-fluoro-4-(trifluoromethyl)phenyl]-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660401-16-1 CAPLUS


CN 1H-1,2,4-Triazole, 5-(2,4-dichloro-5-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-42-3 CAPLUS

CN Pyridine, 3-[1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl]- (9CI) (CA INDEX NAME)



RN 660401-43-4 CAPLUS


CN 1H-1,2,4-Triazole, 5-cyclohexyl-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660401-44-5 CAPLUS


CN 1H-1,2,4-Triazole, 5-(2-cyclohexen-1-yl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-45-6 CAPLUS

CN Benzenesulfonamide, 4-[5-(3,4-difluorophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-46-7 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-47-8 CAPLUS


CN Benzenesulfonamide, 4-[5-(3,4-dichlorophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-48-9 CAPLUS

CN Benzenesulfonamide, 4-[5-(3,4-dimethoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-49-0 CAPLUS


CN Benzenesulfonamide, 4-[5-(3,4-dimethylphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-50-3 CAPLUS


CN Benzenesulfonamide, 4-[5-(3-chloro-4-methylphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-51-4 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-chloro-3-methylphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl] - (9CI) (CA INDEX NAME)



RN 660401-52-5 CAPLUS


CN Benzenesulfonamide, 4-[5-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl] - (9CI) (CA INDEX NAME)



RN 660401-53-6 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-chloro-3-methoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl] - (9CI) (CA INDEX NAME)

10/633,083




RN 660401-54-7 CAPLUS

CN Benzenesulfonamide, 4-[5-(3-fluoro-4-methylphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl] - (9CI) (CA INDEX NAME)



RN 660401-55-8 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-fluoro-3-methylphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl] - (9CI) (CA INDEX NAME)



RN 660401-56-9 CAPLUS


CN Benzenesulfonamide, 4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl] - (9CI) (CA INDEX NAME)

10/633,083




RN 660401-57-0 CAPLUS

CN Benzenesulfonamide, 4-[5-(3,5-dichloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-58-1 CAPLUS


CN Benzenesulfonamide, 4-[3-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-59-2 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-ethoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-60-5 CAPLUS

CN Benzenesulfonamide, 4-[5-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-61-6 CAPLUS


CN Benzenesulfonamide, 4-[5-[4-(1,1-dimethylethyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-62-7 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-cyanophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-63-8 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-aminophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-65-0 CAPLUS


CN Benzenesulfonamide, 4-[5-[4-(dimethylamino)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-66-1 CAPLUS


CN Benzenesulfonamide, 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-67-2 CAPLUS

CN Benzenesulfonamide, 4-[3-(trifluoromethyl)-5-[3-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-68-3 CAPLUS


CN Benzenesulfonamide, 4-[5-(3-methoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-69-4 CAPLUS


CN Benzenesulfonamide, 4-[5-(2-bromophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-70-7 CAPLUS

CN Benzenesulfonamide, 4-[5-(2-methoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-71-8 CAPLUS


CN Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-72-9 CAPLUS


CN Benzenesulfonamide, 4-[5-(2,5-difluorophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-73-0 CAPLUS

CN Benzenesulfonamide, 4-[3-(trifluoromethyl)-5-(2,4,5-trifluorophenyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-74-1 CAPLUS


CN Benzenesulfonamide, 4-[5-(2,3-dichlorophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-75-2 CAPLUS


CN Benzenesulfonamide, 4-[5-(2,4-dichlorophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-76-3 CAPLUS

CN Benzenesulfonamide, 4-[5-(3,5-dimethoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-77-4 CAPLUS


CN Benzenesulfonamide, 4-[5-(2,4-dimethoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-78-5 CAPLUS


CN Benzenesulfonamide, 4-[3-(trifluoromethyl)-5-(3,4,5-trifluorophenyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-79-6 CAPLUS

CN Benzenesulfonamide, 4-[5-[2-fluoro-4-(trifluoromethyl)phenyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-80-9 CAPLUS


CN Benzenesulfonamide, 4-[5-(2-chloro-4-nitrophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-81-0 CAPLUS


CN Benzenesulfonamide, 4-[5-(2,4-dichloro-5-fluorophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 660401-82-1 CAPLUS

CN Benzenesulfonamide, 4-[5-(1,3-benzodioxol-5-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-83-2 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 660401-84-3 CAPLUS

CN Benzenesulfonamide, 4-[5-(2-cyclohexen-1-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/633,083

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:20009 CAPLUS

DOCUMENT NUMBER: 138:73259

TITLE: Preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents

INVENTOR(S): Rast, Bryson; Sakya, Subas Man; Shavnya, Andrei

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1273576	A1	20030108	EP 2002-254339	20020701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2390181	AA	20030105	CA 2002-2390181	20020628
US 2003125368	A1	20030703	US 2002-188713	20020702
JP 2003064061	A2	20030305	JP 2002-196417	20020704
BR 2002002544	A	20030513	BR 2002-2544	20020704
PRIORITY APPLN. INFO.:			US 2001-303186P	P 20010705
OTHER SOURCE(S):	MARPAT 138:73259			
GI				



AB Title compds. I [$m = 0-2$; $R_1 = \text{alk(en/yn)yl}$, alkoxy, alkylcarbonyl, formyl, formamidyl, etc.; $R_3 = \text{H}$, halo, alk(en/yn)yl , alkoxy, etc.; $R_5 = \text{alkyl}$] are prepared. For instance, 4-hydrazinobenzenesulfonamide•HCl was condensed with trifluoroacetamidine to give 4-[N'-(1-amino-2,2,2-trifluoroethylidene)hydrazino]benzenesulfonamide. This intermediate was condensed with benzoyl chloride (CH_2Cl_2 , pyridine, 0°) to give II. Compds. of the invention are evaluated for cyclooxygenase-1 (COX-1) and COX-2 inhibition on canine whole blood; a selected test compound administered at 5 mg/kg (oral gavage) shows significant selectivity for inhibition of COX-2 over COX-1. Example compds. are said to have IC_{50} values of $0.001 \mu\text{M}$ to $3 \mu\text{M}$ with respect to COX-2 inhibition. I are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as osteoarthritis, rheumatoid arthritis, colon cancer and Alzheimer's disease, in mammals (preferably humans, dogs, cats and livestock).


IT 481052-74-8P, 4-(5-Phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-75-9P, 4-(5-(Pyridin-2-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide

481052-76-0P, 4-(5-(Pyridin-3-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-77-1P, 4-(5-(Furan-2-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-78-2P, 4-[5-(Tetrahydrofuran-2-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-79-3P, 4-[5-(Tetrahydropyran-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-80-6P, 4-[5-(2,2-Dimethyltetrahydropyran-4-yl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-81-7P, 4-[5-(4-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-82-8P, 4-[5-(3-Fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-86-2P, 4-(5-Cyclobutyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-87-3P, 4-(5-Cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide 481052-88-4P, 4-[5-(4-tert-Butylcyclohexyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-89-5P, 4-[5-(3-Methylcyclohexyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-90-8P, 4-[5-(3-Methoxycyclohexyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfonamide 481052-91-9P, 4-(5-Cyclopentyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonyl aryl triazoles as anti-inflammatory/analgesic agents)


RN 481052-74-8 CAPLUS

CN Benzenesulfonamide, 4-[5-phenyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-75-9 CAPLUS


CN Benzenesulfonamide, 4-[5-(2-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-76-0 CAPLUS


CN Benzenesulfonamide, 4-[5-(3-pyridinyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 481052-77-1 CAPLUS

CN Benzenesulfonamide, 4-[5-(2-furanyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-78-2 CAPLUS


CN Benzenesulfonamide, 4-[5-(tetrahydro-2-furanyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-79-3 CAPLUS


CN Benzenesulfonamide, 4-[5-(tetrahydro-2H-pyran-4-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 481052-80-6 CAPLUS

CN Benzenesulfonamide, 4-[5-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-81-7 CAPLUS


CN Benzenesulfonamide, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-82-8 CAPLUS


CN Benzenesulfonamide, 4-[5-(3-fluorophenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 481052-86-2 CAPLUS

CN Benzenesulfonamide, 4-[5-cyclobutyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-87-3 CAPLUS


CN Benzenesulfonamide, 4-[5-cyclohexyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-88-4 CAPLUS


CN Benzenesulfonamide, 4-[5-[4-(1,1-dimethylethyl)cyclohexyl]-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083




RN 481052-89-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(3-methylcyclohexyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-90-8 CAPLUS


CN Benzenesulfonamide, 4-[5-(3-methoxycyclohexyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)



RN 481052-91-9 CAPLUS

CN Benzenesulfonamide, 4-[5-cyclopentyl-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

10/633,083



REFERENCE COUNT:

3


THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/633,083

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:356250 CAPLUS
DOCUMENT NUMBER: 134:353312
TITLE: Preparation of 5-aryl-1H-1,2,4-triazoles as inhibitors
of cyclooxygenase-2
INVENTOR(S): Pascal, Jean-claude; Carniato, Denis
PATENT ASSIGNEE(S): Laboratoire Theramex S.A., Monaco
SOURCE: Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1099695	A1	20010516	EP 1999-402784	19991109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2390649	AA	20010517	CA 2000-2390649	20001106
WO 2001034577	A1	20010517	WO 2000-EP10956	20001106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000015440	A	20020702	BR 2000-15440	20001106
EP 1246809	A1	20021009	EP 2000-983110	20001106
EP 1246809	B1	20030716		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003513961	T2	20030415	JP 2001-536525	20001106
NZ 518682	A	20030725	NZ 2000-518682	20001106
AT 245148	E	20030815	AT 2000-983110	20001106
PT 1246809	T	20031128	PT 2000-983110	20001106
ES 2203538	T3	20040416	ES 2000-983110	20001106
AU 778819	B2	20041223	AU 2001-19985	20001106
RU 2249588	C2	20050410	RU 2002-115284	20001106
ZA 2002003165	A	20030422	ZA 2002-3165	20020422
NO 2002002202	A	20020508	NO 2002-2202	20020508
US 6803380	B1	20041012	US 2002-111424	20020517
PRIORITY APPLN. INFO.:			EP 1999-402784	A 19991109
			WO 2000-EP10956	W 20001106
OTHER SOURCE(S):			MARPAT 134:353312	
GI				



I

AB The title compds. [I; R₁ = H, alkyl, haloalkyl, etc.; R₂ = alkyl,

10/633,083


cycloalkyl, Ph, etc.; R3 = H, halo, OH, etc.; R4 = alkyl, NH2, (di)alkylamino, etc.], potent and selective COX-2 inhibitors, were prepared E.g., a 2-step synthesis of I [R1 = CF3; R2 = 4-BrC6H4; R3 = H; R4 = Me], one of the most potent compound in the series which appeared to be about 10 times more potent than nimesulide, was given.

IT 339264-29-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-aryl-1H-1,2,4-triazoles as inhibitors of cyclooxygenase-2)

RN 339264-29-8 CAPLUS

CN 1H-1,2,4-Triazole, 1,5-bis[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT